United Kingdom · Question · Written question
UIN 443
Puberty Suppressing Hormones: Clinical Trials
Original
Introduced
17 July 2024
Last action
29 July 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
29 July 2024
Summary
To ask the Secretary of State for Health and Social Care, with reference to Recommendation 6 on page 35 of the Cass Review, published in April 2024, what plans he has for the extent of a further clinical trial on puberty blockers; and what his planned tim
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
17 July 2024
Written question
To ask the Secretary of State for Health and Social Care, with reference to Recommendation 6 on page 35 of the Cass Review, published in April 2024, what plans he has for the extent of a further clinical trial on puberty blockers; and what his planned tim
Source: Commons
29 July 2024
Answer
The expert Cass Review, which is one of the most comprehensive reviews of gender identity services for children and young people to date, states that the rationale for early puberty suppressing hormones to treat gender dysphoria is unclear and the effects...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-07-17/443
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1721728
- uk · wq-1721728 · source updated 29 July 2024